title: Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis.
abstract: Fibulin-3 has emerged as a promising novel biomarker in conforming or monitoring malignant pleural mesothelioma (MPM). This study sought to evaluate the diagnostic and prognostic efficacies of humoral fibulin-3 for MPM. Seven eligible publications comprising 468 MPM cases for diagnosis, and 138 for prognosis were identified. Results manifested that humoral fibulin-3 sustained a pooled sensitivity of 0.62 (95% CI: 0.45-0.77) and specificity of 0.82 (95% CI: 0.73-0.89) in discriminating MPM patients from cancer-free individuals, corresponding to an AUC (area under the curve) of 0.81. For the survival analysis, fibulin-3 expression was not markedly associated with overall survival (OS) time of the MPM patients [HR (hazard ratio): 1.84, 95% CI: 0.75-4.56, P = 0.185]. In the subgroup analyses stratified by test matrix and ethnicity, data revealed that serum-based fibulin-3 examination achieved superior accuracy than plasma-based analysis (sensitivity: 0.77 versus 0.54; specificity: 0.85 versus 0.77; AUC: 0.92 versus 0.69); additionally, testing of fibulin-3 in Europeans retained higher efficacy than those in Americans and Australians. Taken together, fibulin-3 confers a relatively high diagnostic efficacy and is acceptable to be an auxiliary biomarker to aid in MPM identification.
authors.affiliation: Department of Clinical Laboratory, Hennan Province Hospital of TCM, Zhengzhou, Henan, China.
authors.forename: Dongxu
authors.initials: D
authors.lastname: Pei
authors.affiliation: Department of Clinical Laboratory, Hennan Province Hospital of TCM, Zhengzhou, Henan, China.
authors.forename: Yongwei
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Clinical Laboratory, Hennan Province Hospital of TCM, Zhengzhou, Henan, China.
authors.forename: Xinwei
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Clinical Laboratory, Hennan Province Hospital of TCM, Zhengzhou, Henan, China.
authors.forename: Sha
authors.initials: S
authors.lastname: Yan
authors.affiliation: Department of Clinical Laboratory, Hennan Province Hospital of TCM, Zhengzhou, Henan, China.
authors.forename: Xiaolan
authors.initials: X
authors.lastname: Guo
authors.affiliation: Department of Clinical Laboratory, Hennan Province Hospital of TCM, Zhengzhou, Henan, China.
authors.forename: Xiaona
authors.initials: X
authors.lastname: Xu
authors.affiliation: Department of Clinical Laboratory, Anyang Hospital of Traditional Chinese Medicine.
authors.forename: Xiaoxia
authors.initials: X
authors.lastname: Guo
mesh_terms: D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000032:analysis*; D016326:Extracellular Matrix Proteins / Q000032:analysis / Q000096:biosynthesis*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis*; D008654:Mesothelioma / Q000175:diagnosis*; D000086002:Mesothelioma, Malignant; D010997:Pleural Neoplasms / Q000175:diagnosis*; D011379:Prognosis; D012372:ROC Curve; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; C119630:EFEMP1 protein, human; D016326:Extracellular Matrix Proteins
keywords: biomarker; diagnosis; fibulin-3; malignant pleural mesothelioma; prognosis